Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) Q4 2015 Earnings Conference Call - Final Transcript

Feb 23, 2016 • 04:30 pm ET

Previous

Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) Q4 2015 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Analyst
John Boris

around that? Secondly, on Xyrem, in the back half, there will be a competitor that's rolling out a clinical. Have you taken into account that a significant number of patients could be taken out of market -- I think they're enrolling about 300 in a competitive trial, with a substantial number of those coming out of the U.S. largely. Is that factored into your volume guidance? Thanks.

Executive
Bruce Cozadd

Yes, John. Certainly aware of the Celgene settlement but really can't comment on specifically how that might apply to our situation. But interesting deal, and you draw some parallels there that I think are relevant. Our Xyrem guidance does take into account what we think will happen to our business this year.

Analyst
John Boris

Thanks.

Operator
Operator

Thank you. And our last question is from the line of David Buck with Northland Capital Markets. Your line is open. Please go ahead.

Analyst
David Buck

Yes, thanks for taking the follow up. Maybe for Matt, can you talk a little bit about what the sales and earnings impact was from foreign exchange overall for 2015 and what the expectation embedded in the guidance is toward the sales and EPS impact from foreign exchange? Thanks.

Executive
Bruce Cozadd

Yes, sure, David. The impact overall for 2015 of FX was $22 million, so roughly $7 million with respect to Erwinaze, roughly $14 million rounded up to $22 million, about $14 million for Defitelio. And bottom line as we mentioned many times, was really relatively neutral, in fact, was maybe a slight gain, I think most of which occurred in the fourth quarter but in less than $2 million.

And that relates to some balance sheet exposures we had in where we in terms of how we held our cash and intercompany loans, but also related to having a significant number of our expenses denominated in euro, given both European operations and our substantial presence in Ireland.

Operator
Operator

Thank you, and that does conclude today's Q&A portion of the call. I'd like to turn the call back over to Kathee Littrell for any closing remarks.

Executive
Kathee Littrell

Thanks, Cath. Thank you again for joining us today. We will be participating in the Cowen Healthcare Conference and the Barclays Healthcare Conference this quarter, and we hope to see many of you there. This will now end our call.

Operator
Operator

[Operator Closing Remarks]